Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R
Lung Tumor Group, Vancouver Center, British Columbia Cancer Agency, Canada.
J Clin Oncol. 1998 Oct;16(10):3323-8. doi: 10.1200/JCO.1998.16.10.3323.
To evaluate the efficacy of an abbreviated treatment plan consisting of two cycles of chemotherapy plus thoracic irradiation in a population of limited-stage small-cell lung cancer (LSCLC) patients who were elderly, infirm, or noncompliant with standard-duration therapy.
Fifty-five LSCLC patients (median age, 73) were treated with one cycle of cyclophosphamide, doxorubicin, and vincristine (CAV) followed 3 weeks later by one cycle of etoposide and cisplatin (EP). Both regimens were administered at conventional full dose. Thoracic irradiation (20 to 30 Gy) was delivered concurrently with EP.
Complete response occurred in 28 patients (51%) and partial response in 21 (38%). The median survival time was 54 weeks; the 2-year survival rate was 28% and the actual 5-year survival rate was 18%. Three patients died of toxicity.
Elderly, infirm, or noncompliant LSCLC patients who are unable to receive standard-duration chemotherapy may have useful palliation and potential for long-term survival with abbreviated chemotherapy (two cycles) and thoracic irradiation.
评估由两个周期化疗加胸部放疗组成的简化治疗方案，对老年、体弱或不依从标准疗程治疗的局限期小细胞肺癌（LSCLC）患者的疗效。
55例LSCLC患者（中位年龄73岁）接受了一个周期的环磷酰胺、阿霉素和长春新碱（CAV）治疗，3周后接受一个周期的依托泊苷和顺铂（EP）治疗。两种方案均采用常规全剂量给药。胸部放疗（20至30 Gy）与EP同步进行。
28例患者（51%）出现完全缓解，21例（38%）出现部分缓解。中位生存时间为54周；2年生存率为28%，实际5年生存率为18%。3例患者死于毒性反应。
无法接受标准疗程化疗的老年、体弱或不依从的LSCLC患者，通过简化化疗（两个周期）和胸部放疗可能获得有效的姑息治疗及长期生存的可能。
